

Patents

Serial No.: 10/044,275

Response Dated November 5, 2003

Response to Office Action of May 5, 2003

AMENDMENTS TO THE SPECIFICATION

1. Please replace the sentence beginning at page 2, line 3, which starts with "See for example" with the following amended paragraph:

See for example, Schirner, A., and Haneke, E., *Rosacea and Metronidazole*, Acta Dermatologica, 7,27-30 (1981); and Nielsen, P.G., *A Double Blind Study for 1% Metronidazole Cream Reserves versus Systemic Oxytetracycline Therapy for Rosacea*, British Journal of Dermatology, 109, 63-65, (1983).

2. Please replace the sentence beginning at page 2, line 17, which starts with "A causative role" with the following amended paragraph:

A causative role has also been suggested for the hair follicle mite, *Demodex*, ~~C.E. Bonnard~~ E. Bonnar, et al., *The Demodex Mite Population*, J. Amer. Acad. Dermatology, Vol. 28, No. 3, pp. 443-447, March 1993.

3. Please replace the paragraph beginning at page 2, line 21, which starts with "Missing in the art" with the following amended paragraph:

Missing in the art is a convenient means to ensure patient compliance with topical administration of a metronidazole solution. At present, there is no commercially available pledget form of metronidazole. Wang, et al. ~~Degradation~~ Degradation *Kinetics of Metronidazole in Solution*, J. Pharm Sciences, 82 (1), pp 95-97 (Jan. 1993) teaches that metronidazole degrades in solution.